-
HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
•
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed that it has received tacit clinical approval from the National Medical Products Administration (NMPA) for its drug candidate HF50. This T-cell redirecting antibody fragment-anchored liposomes (TRAFsomes) product will be tested in clinical trials for HER-2…
-
HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors
•
Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the initiation of dosing for the first patient in a clinical trial of its candidate HFK1. This investigational drug is an immunoliposome encapsulating doxorubicin, aimed at targeting various solid tumors. The trial is being conducted concurrently…
-
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
•
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American Society of Clinical Oncology (ASCO) annual meeting, showcasing preliminary data from a Phase Ia trial for its lead pipeline candidate, HF1K16. The trial, which focused on refractory metastatic cancer patients, indicated that HF1K16 was well…
